Corey Davis, J.D., M.S.P.H., serves as Director of the Network’s Harm Reduction Legal Project, which works to address the legal and policy barriers that impede the establishment and expansion of evidence-based harm reduction measures such as naloxone distribution, syringe access programs, and access to evidence-based substance use disorder treatment. Corey and his team provide guidance and consultation in navigating the often extremely confusing maze of existing laws and regulations that hamper harm reduction initiatives.
Corey was previously a Senior Attorney at the National Health Law Program (NHeLP), where he helped to advance access to quality health care for low-income and underserved individuals. Before joining NHeLP Corey served as Employment Rights Attorney at Equality Advocates Pennsylvania, where he represented lesbian, gay, bisexual and transgender (LGBT) individuals before administrative commissions and in state and federal courts. He previously oversaw a street-based legal clinic sited at Philadelphia’s syringe exchange program.
Corey has served as chair of a county board of health, chair of the board of the North Carolina Harm Reduction Coalition, and vice-chair of the North Carolina Harm Public Health Foundation, among other positions. He is a recipient of the International AIDS Society’s Young Investigator Award and has published extensively in the lay and academic press. Corey received his B.S. from the Indiana University of Pennsylvania, his M.S.P.H. from the University of North Carolina at Chapel Hill and his J.D. from Temple University. Corey is barred in Pennsylvania and New Jersey as well as various federal courts.
by Overview The United States continues to experience an epidemic of drug-related harm, most of which could be prevented by expanding existing interventions,…
The United States continues to experience an unprecedented level of drug-related harm. While the failure to prevent this harm is most notable in the number of overdose deaths, which are now at their highest level on record, it is evident in other areas as well. Of particular importance from a policy perspective, bloodborne disease infections related to syringe sharing are also on the rise, with recent outbreaks in Kentucky, Massachusetts, and Indiana, among other states. Cases of infective endocarditis, which is caused largely by unsafe injection, are increasing as well.
This paper identifies barriers to OAT access and potential solutions to improve OAT uptake in eight sectors.
The Network’s Harm Reduction Legal Project works to address the legal and policy barriers that impede the establishment and expansion of evidence-based harm reduction measures such as naloxone distribution, syringe access programs, and access to evidence-based substance use disorder treatment. One of the questions frequently received by the Project is whether federal law prohibits harm reduction organizations and similar groups who are authorized to distribute naloxone from mailing the medication.
In this Q&A, Corey Davis, deputy director of the Network’s Southeastern Region Office and director of the Network’s Harm Reduction Legal Project; and Amy Lieberman, senior attorney, for the Network’s Harm Reduction Legal Project, discuss some of the key elements in the chapter they authored, Access to Care for Individuals with Opioid Use Disorder, for the Report.
This fact sheet briefly summarizes the state of the law in Idaho related to naloxone access, overdose Good Samaritan protections, and access to injection equipment.
This webinar focused on the legal and regulatory modifications during COVID-19, how they are being used to increase access treatment for opioid use disorder, and opportunities to permanently increase access to medications.
While states have passed various laws designed to increase access to naloxone, a life-saving opioid overdose reversal medication, none explicitly address the legality of dispensing naloxone that is past its expiration date. This fact sheet discusses whether Georgia laws forbid the prescription, dispensing, distribution, possession, or administration of expired naloxone and whether such actions impact the risk of civil liability for medical professionals who prescribe or dispense naloxone or laypeople who distribute or administer it.
This fact sheet discusses whether District of Columbia laws forbid the prescription, dispensing, distribution, possession, or administration of expired naloxone and whether such actions impact the risk of civil liability for medical professionals who prescribe or dispense naloxone or laypeople who distribute or administer it.
The Drug Enforcement Administration (DEA) has temporarily waived or clarified several regulations that may act as barriers to providing life-saving medications to those undergoing treatment for opioid use disorder during the COVID-19 Pandemic. These changes have the potential to dramatically increase access to these medication and the DEA should strongly consider extending many of these changes for the duration of the opioid public health emergency, which will remain even after the threat from COVID-19 subsides.
This fact sheet discusses whether Illinois laws forbids the prescription, dispensing, distribution, possession, or administration of expired naloxone.
The medications methadone and buprenorphine are extremely effective in reducing the harms associated with opioid use disorder. In light of the ongoing public health emergency associated with COVID-19 the federal government has recently taken a number of steps to increase access to these lifesaving medications.
